Singhal Priya, Head of Development, has demonstrated a consistent pattern of insider activity focused exclusively on Biogen Inc. (BIIB) over the past several years, as reflected in SEC Form 4 filings. With 35 reported transactions, all activity has been concentrated on selling shares, totaling approximately $2.36 million in value. Notably, there have been no reported purchases of BIIB stock during this period, indicating a clear selling bias. Recent filings highlight this trend, with six sell transactions occurring between January 2025 and February 2026, including significant sales such as $531,547.80 on February 9, 2026, and $284,066.16 on February 6, 2026. Earlier transactions, such as a $69,045.35 sale on September 2, 2025, and a $57,962.26 sale on February 22, 2024, further underscore this sustained divestment strategy.
The transactions also include several filings coded as "F" (indicating the acquisition of shares through derivative securities like stock options) and "M" (representing transactions involving equity swaps or other derivative instruments), though these did not result in direct monetary value. For example, multiple "F" filings on February 6, 2026, and January 30, 2026, were accompanied by corresponding sales, suggesting the exercise of options followed by immediate liquidation. This pattern aligns with Priya’s broader approach of reducing equity exposure in BIIB. While the reasons behind these sales remain undisclosed, the data reveals a consistent and methodical reduction in holdings over time, with no indication of reinvestment into the company’s stock.
AI-assisted summary